| Literature DB >> 29344273 |
Cheng-Yuan Gu1,2, Gao-Xiang Li1,2, Yu Zhu1,2, Hua Xu1,2, Yao Zhu1,2, Xiao-Jian Qin1,2, Dai Bo1,2, Ding-Wei Ye1,2.
Abstract
BACKGROUND: Cytochrome P450 1B1 (CYP1B1) is a key enzyme in its oestrogen metabolism pathway, giving rise to hydroxylation and conjugation. Functionally relevant genetic variants within CYP1B1 may affect the telomere length and subsequently lead to prostate carcinogenesis.Entities:
Keywords: CYP1B1; prostate cancer; single nucleotide polymorphism; susceptibility.
Year: 2018 PMID: 29344273 PMCID: PMC5771334 DOI: 10.7150/jca.21774
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Characteristics of PCa Cases and Controls
| Variables | Cases (%) | Controls (%) | |
|---|---|---|---|
| Age | 69.1 ± 8.2 | 68.6 ± 8.9 | 0.828 |
| ≤ 64 | 291 (28.7) | 308 (29.3) | |
| 65-75 | 496 (48.9) | 500 (47.5) | |
| > 75 | 228 (22.5) | 244 (23.2) | |
| Smoking status | |||
| Never | 406 (40.0) | 412 (39.2) | 0.697 |
| Ever | 609 (60.0) | 640 (60.8) | |
| PSA value (ng/ml) | |||
| < 10 | 180 (19.4) | ||
| 10-20 | 195 (21.0) | ||
| > 20 | 552 (59.6) | ||
| Missing | 88 (8.7) | ||
| Gleason score | |||
| ≤ 7 (3+4) | 317 (31.2) | ||
| ≥ 7 (4+3) | 606 (59.7) | ||
| Missing | 92 (9.1) | ||
| Stage of disease | |||
| I | 5 (0.5) | ||
| II | 434 (42.8) | ||
| III | 142 (14.0) | ||
| IV | 356 (35.1) | ||
| Missing | 78 (7.7) |
PSA: prostate-specifc antigen
Association of CYP1B1 SNPs with PCa Risk
| SNP | Cases, No. (%) | Controls, No. (%) | OR (95% CI) | |
|---|---|---|---|---|
| rs9341266 | ||||
| GG | 774 (76.3) | 816 (77.6) | 1.00 | |
| AG | 218(21.5) | 215 (20.4) | 1.07 (0.87-1.32) | 0.533 |
| AA | 23 (2.3) | 21 (2.0) | 1.15 (0.63-2.10) | 0.649 |
| AG/AA vs. GG | 1.08 (0.88-1.32) | 0.477 | ||
| GG/AG vs. AA | 1.13 (0.62-2.06) | 0.683 | ||
| rs162549 | ||||
| TT | 787 (77.5) | 811 (77.1) | 1.00 | |
| AT | 209 (20.6) | 222 (21.1) | 0.95 (0.77-1.18) | 0.636 |
| AA | 19 (1.9) | 19 (1.8) | 1.01 (0.53-1.93) | 0.971 |
| AT/AA vs. TT | 0.96 (0.78-1.17) | 0.660 | ||
| TT/AT vs. AA | 1.02 (0.54-1.95) | 0.944 | ||
| rs10916 | ||||
| TT | 808 (79.6) | 856 (81.4) | 1.00 | |
| GT | 192 (18.9) | 183 (17.4) | 1.12 (0.89-1.40) | 0.333 |
| GG | 15 (1.5) | 13 (1.2) | 0.75 (0.50-1.11) | 0.152 |
| GT/GG vs. TT | 1.13 (0.91-1.40) | 0.289 | ||
| TT/GT vs. GG | 1.21 (0.57-2.56) | 0.617 | ||
| rs162562 | ||||
| AA | 695 (68.5) | 711 (67.6) | 1.00 | |
| AC | 287 (28.3) | 305 (29.0) | 0.97 (0.80-1.17) | 0.719 |
| CC | 33 (3.3) | 36 (3.4) | 0.96 (0.59-1.55) | 0.854 |
| AC/CC vs. AA | 0.96 (0.80-1.16) | 0.700 | ||
| CC/AC vs.CC | 0.97 (0.60-1.56) | 0.887 | ||
| rs2551188 | ||||
| CC | 541 (53.3) | 558 (53.0) | 1.00 | |
| CT | 423 (41.7) | 421 (40.0) | 1.05 (0.88-1.26) | 0.564 |
| TT | 51 (5.0) | 73 (6.9) | 0.72 (0.49-1.05) | 0.086 |
| CT/TT vs. CC | 1.00 (0.84-1.19) | 0.964 | ||
| CC/CT vs.TT | 0.70 (0.49-1.02) | 0.060 | ||
| rs9341250 | ||||
| CC | 955 (94.1) | 985 (93.6) | 1.00 | |
| AC | 58 (5.7) | 64 (6.1) | 0.96 (0.66-1.38) | 0.806 |
| AA | 2 (0.2) | 3 (0.3) | 0.66 (0.11-3.94) | 0.644 |
| AC/AA vs. CC | 0.94 (0.66-1.35) | 0.741 | ||
| CC/AC vs. AA | 0.66 (0.11-3.95) | 0.646 | ||
| rs1056827 | ||||
| CC | 668 (65.8) | 679 (64.5) | 1.00 | |
| AC | 303 (29.9) | 327 (31.1) | 0.94 (0.78-1.14) | 0.543 |
| AA | 44 (4.3) | 46 (4.4) | 0.98 (0.64-1.50) | 0.908 |
| AC/AA vs. CC | 0.95 (0.79-1.14) | 0.555 | ||
| CC/AC vs. AA | 0.99 (0.65-1.52) | 0.976 | ||
| rs1056836 | ||||
| CC | 728 (71.7) | 705 (67.0) | 1.00 | |
| CG | 274 (27.0) | 323 (30.7) | 0.82 (0.68-0.99) | 0.041 |
| GG | 13 (1.3) | 24 (2.3) | 0.54 (0.27-1.07) | 0.079 |
| CG/GG vs. CC | 0.80 (0.66-0.97) | 0.020 | ||
| CC/CG vs. GG | 0.57 (0.29-1.14) | 0.111 |
HWE: Hardy-Weinberg equilibrium. aAdjusted for age and smoking status.
The results were in bold if P < 0.05.
Association between CYP1B1 SNPs and RTL
| SNP | Genotype | Short RTL, n (%) | Long RTL, n (%) | OR (95% CI)a | |
|---|---|---|---|---|---|
| rs9341266 | GG | 58 (27.9) | 64 (29.4) | 1.00 | |
| AG/AA | 150 (72.1) | 154 (70.6) | 1.08 (0.71-1.64) | 0.737 | |
| rs162549 | TT | 44 (21.2) | 48 (22.0) | 1.00 | |
| AT/AA | 164 (78.8) | 170 (78.0) | 1.05 (0.66-1.67) | 0.828 | |
| rs10916 | TT | 35 (16.8) | 54 (24.8) | 1.00 | |
| GT/GG | 173 (83.2) | 164 (75.2) | 1.63 (1.01-2.62) | 0.045 | |
| rs162562 | AA | 60 (28.8) | 66 (30.3) | 1.00 | |
| AC/CC | 148 (71.2) | 152 (69.7) | 1.07 (0.71-1.62) | 0.747 | |
| rs2551188 | CC | 82 (39.4) | 103 (47.2) | 1.00 | |
| CT/TT | 126 (60.6) | 115 (52.8) | 1.38 (0.94-2.02) | 0.104 | |
| rs9341250 | CC | 13 (6.2) | 17 (7.8) | 1.00 | |
| AC/AA | 195 (93.8) | 201 (92.2) | 1.27 (0.60-2.68) | 0.533 | |
| rs1056827 | CC | 67 (32.2) | 69 (31.7) | 1.00 | |
| AC/AA | 141 (67.8) | 149 (68.3) | 0.98 (0.65-1.47) | 0.901 | |
| rs1056836 | CC | 67 (32.2) | 50 (22.9) | ||
| CG/GG | 141 (67.8) | 168 (77.1) | 1.60 (1.04-2.45) | 0.033 |
RTL: Relative telomere length aAdjusted for age and smoking status.